SCIENTIFIC PROGRAMME
SESSION I
HOW I TREAT
SMOLDERING MYELOMA
(SMM)
SESSION II
HOW I TREAT NEWLY
DIAGNOSED MULTIPLE
MYELOMA
SESSION III
FROM RISK
STRATIFICATION TO
RISK-BASED THERAPY?
DEBATE 1
SHOULD WE USE MRD
TESTING TO DETERMINE
THERAPY IN MULTIPLE
MYELOMA?
DEBATE 2
IS THERE A FUTURE ROLE
OF AUTOLOGOUS STEM
CELL TRANSPLANTATION?
SESSION IV
HOW I TREAT RELAPSED
MULTIPLE MYELOMA
DEBATE 3
SHOULD EVERY PATIENT
RECEIVE DARATUMUMAB
IN FIRST LINE?
ROUNDTABLE
MULTIPLE MYELOMA
FROM THE PERSPECTIVE
OF FDA/EMEA AND
FOUNDATIONS
SESSION V
YOU CAN’T BE IMMUNE
FOR IMMUNE THERAPY
ANYMORE
SESSION VI
OTHER PLASMA CELL
DYSCRASIAS
KEYNOTE LECTURES
THE FUTURE OF
MULTIPLE MYELOMA
SELECTED ABSTRACTS
FOR AN ORAL
PRESENTATION
ABSTRACTS SELECTED
AS POSTERS
DISCLOSURES
14:45-15:55 ROUNDTABLE – Novel agents in the treatment of multiple myeloma from the perspective of
FDA/EMEA and Foundations
Chairs: Hermann Einsele (Würzburg) and Sonja Zweegman (Amsterdam)
14:45-14:50 Introduction Hermann Einsele (Würzburg),
Sonja Zweegman (Amsterdam)
14:50-15:05 Food and Drug Administration Bindu Kanapuru (Bethesda)
15:05-15:20 Multiple Myeloma Research Foundation perspective: Daniel Auclair (Boston)
Multiple myeloma drug development in 2021
15:20-15:35 Access to drugs in Europe Jean-Luc Harousseau (Nantes)
15:35-15:55 Discussion
15:55-16:05 Coffee break
SESSION V- You can’t be immune for immune therapy anymore
Chair: Hermann Einsele (Würzburg)
16:05-16:10 Introduction Hermann Einsele (Würzburg)
16:10-16:30 Interactive case: Bi- and trispecific antibodies Hermann Einsele (Würzburg)
in multiple myeloma
16:30-16:50 Case-based lecture : CART in multiple myeloma Nina Shah (San Francisco)
16:50-17:10 Case-based lecture : Antibody based immunotherapy Niels Van De Donk (Amsterdam)
17:10-17:30 Case-based lecture : Future immunotherapies Eric Smith (New York)
in multiple myeloma
17:30-17:40 Brief oral communications
17:30-17:35 Cartitude-1, a phase 1b/2 study of Ciltacabtagene Deepu Madduri (New York)
Autoleucel in relapsed/refractory multiple myeloma (RRMM)
17:35-17:40 Teclistamab, a B-Cell maturation antigen (BCMA) X CD3 Hareth Nahi (Stockholm)
bispecific antibody, in relapsed and/or refractory multiple myeloma (RRMM): updated phase 1 results
17:40-18:10 Panel discussion
Sunday, April 18, 2021
10:20-11:20 SATELLITE SYMPOSIUM
Anti B-cell maturation antigen (BCMA) :
the fourth pillar treatment in relapsed/refractory multiple myeloma
Chair: Xavier Leleu (Poitiers)
Speakers: Javier de la Rubia (Valencia), Elena Zamagni (Bologna)
This symposium is organised and funded by GSK
5